ArticleThe Lancet regional health. Western Pacific2022
Epidemiology of Moyamoya disease in China: A nationwide hospital-based study.
Article in The Lancet regional health. Western Pacific, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Remote ischemic conditioning prevents ischemic cerebrovascular events in children with moyamoya disease: a randomized controlled trial.World journal of pediatrics : WJP · 2024Trial
- Exploratory profiling of serum small extracellular vesicle-associated miRNAs as candidate biomarkers for Moyamoya disease.Biochemistry and biophysics reports · 2026Article
- Chinese expert consensus on the treatment and diagnosis of moyamoya disease and moyamoya syndrome (2024).Stroke and vascular neurology · 2026Article
- Epidemiological and clinical characteristics of hospitalized patients with cardiomyopathies in China: a nationwide retrospective analysis.BMC public health · 2026Article
- Hospitalization costs and out-of-pocket expenses for stroke patients in mainland China.BMC health services research · 2026Article
- Genetic Biomarkers for Moyamoya Disease Beyond Angiography.Journal of clinical neurology (Seoul, Korea) · 2026Article
- Unusual Synchronous Arbitrary-Gate Doppler Spectra Enable Intraoperative Hemodynamic Warning of Cerebral Hyperperfusion Syndrome on Moyamoya Disease.CNS neuroscience & therapeutics · 2026Article
- Risk Factors Influencing Disease Onset and Surgical Outcomes in Moyamoya Disease.Journal of multidisciplinary healthcare · 2026Article
- LPIN3 emerges as a diagnostic biomarker in Moyamoya disease revealing immune-lipid metabolic crosstalk.Frontiers in genetics · 2026Article
- Dual-center development and validation of a LDL-C and TC based nomogram for preoperative hemorrhagic risk in adult moyamoya disease.Frontiers in nutrition · 2026Article
- Advances in cerebrovascular reserve function assessment for moyamoya disease.BMJ neurology open · 2026Review
- Spatiotemporal distribution and clinical manifestations of moyamoya disease in Jiangxi Province, China: a retrospective hospital-based study.BMJ public health · 2026Article
- How retinal artery occlusion reveals moyamoya disease-a case series and descriptive study.International journal of ophthalmology · 2026Article
- Long-term clinical and radiological outcomes of extracranial-intracranial bypass in hemorrhagic patients with Moyamoya disease: A single-center observational study of 45 cases.Neurosurgical review · 2025Observational
- Development and validation of a scoring system to evaluate and clinically manage postoperative acute infarction complications in moyamoya disease.Communications medicine · 2025Article
- The Role of TCD in Assessing Postoperative Collateral Development and Long-Term Clinical Outcome in Moyamoya Disease.CNS neuroscience & therapeutics · 2025Article
- Non-Invasive Diagnosis of Moyamoya Disease Using Serum Metabolic Fingerprints and Machine Learning.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- The Role of Immune Cells in Moyamoya Disease.Brain sciences · 2025Review
- Epidemiology of pulmonary embolism in China, 2021: a nationwide hospital-based study.The Lancet regional health. Western Pacific · 2025Article
- Immunoglobulin G N-Glycosylation and Inflammatory Factors: Analysis of Biomarkers for the Diagnosis of Moyamoya Disease.Journal of inflammation research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe national epidemiologic data in mainland China is still absent for moyamoya disease (MMD).
methodsThis study was a nationwide hospital-based observational retrospective study to estimate epidemiological characteristics of MMD. The data was based on the Hospital Quality Monitoring System (HQMS), a national database which covers all tertiary hospitals in mainland China. This system consistently collects medical records including demographic characteristics, diagnoses, procedures, and expenses etc. for all inpatients. MMD was identified by ICD-10 code (I67·5) in HQMS.
findingsA total of 47,443 new-onset patients with total 69,680 hospitalization records from 1312 hospitals during 2016 to 2018 were included. The annual incidence rate was 1·14 per 100,000 inhabitants (95% CI, 1·12-1·16) and approximately a 2-fold increase from 2016 to 2018. The incidence in children (0·18 per 100,000 inhabitants per year; 95% CI, 0·17-0·20) was significantly lower than that in adults (1·40 per 100,000; 95% CI, 1·38-1·42) (
interpretationOur study reported the annual incidence of MMD was 1·14 per 100,000 inhabitants in mainland China during 2016 to 2018, and it was increasing year by year. The geographical distribution of MMD incidence presented as a clustered regional pattern, which may provide new view for future study on the etiology for MMD.
fundingNational Natural Science Foundation of China and "13th Five-Year Plan" National Science and Technology Supporting Plan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.